Retension Pharmaceuticals, Inc.
RTSN Nasdaq
SEC CIK 2002988
Follow Retension Pharmaceuticals
Weekly email: filings, results
Net income
−$5.9M
−301% vs same quarter last year
EPS, diluted
−$7.33
−300.5% vs same quarter last year
Operating income
−$6M
−260.8% vs same quarter last year
Source: SEC XBRL filings · latest filing